Crewe Advisors LLC Gilead Sciences, Inc. Transaction History

Crewe Advisors LLC

$859 Million
Q3 2024

A detailed history of Crewe Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 1,675 shares of GILD stock, worth $151,068. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,675

Previous 1,670 0.3%

Holding current value

$151,068

Previous $114,000 22.81%

% of portfolio

0.02%

Previous 0.01%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$66.59 - $83.99 $332 - $419	5 Added 0.3%	1,675 $140,000
Q2 2024 Jul 29, 2024	SELL	$63.15 - $72.88 $16,040 - $18,511	-254 Reduced 13.2%	1,670 $114,000
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $137,719 - $167,945	1,924 New	1,924 $140,000
Q2 2023 Jul 28, 2023	SELL	$76.01 - $86.7 $6,460 - $7,369	-85 Reduced 6.98%	1,133 $87,000
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $10,050 - $11,450	-130 Reduced 9.64%	1,218 $101,000
Q4 2022 Feb 07, 2023	SELL	$62.32 - $89.47 $21,936 - $31,493	-352 Reduced 20.71%	1,348 $115,000
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $40,308 - $46,042	677 Added 66.18%	1,700 $105,000
Q2 2022 Aug 02, 2022	BUY	$57.72 - $65.01 $4,213 - $4,745	73 Added 7.68%	1,023 $63,000
Q1 2022 Apr 27, 2022	SELL	$57.92 - $72.58 $347 - $435	-6 Reduced 0.63%	950 $56,000
Q4 2021 Feb 10, 2022	BUY	$64.88 - $73.64 $62,025 - $70,399	956 New	956 $69,000
Q4 2020 Jan 27, 2021	SELL	$56.65 - $64.55 $3,399 - $3,873	-60 Closed	0 $0
Q3 2020 Oct 13, 2020	BUY	$62.1 - $78.08 $3,726 - $4,684	60 New	60 $4,000
Q4 2019 Feb 05, 2020	SELL	$61.62 - $67.78 $25,695 - $28,264	-417 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $24,216 - $31,600	-400 Reduced 48.96%	417 $26,000
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $58,129 - $68,235	817	817 $59,000

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.

Account

Crewe Advisors LLC Gilead Sciences, Inc. Transaction History